de la Campa, Adela GFerrandiz-Avellano, Maria-JoseTubau, FePallarés, RománManresa, FedericoLiñares, Josefina2019-08-132019-08-132003-04Antimicrob Agents Chemother. 2003 Apr;47(4):1419-22.0066-4804http://hdl.handle.net/20.500.12105/8235Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy. One ciprofloxacin-susceptible strain was isolated before treatment, and four ciprofloxacin-resistant strains were isolated during treatment. The resistant strains were derived from the susceptible strain either by a parC mutation (low-level resistance) or by parC and gyrA mutations (high-level resistance). This study shows that ciprofloxacin therapy in a patient colonized by susceptible S. pneumoniae may select fluoroquinolone-resistant mutants.engAMAnti-Infective AgentsBronchiectasisCiprofloxacinDrug Resistance, BacterialHumansMaleMiddle AgedStreptococcus pneumoniaeMutationGenetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasisAtribución-NoComercial-CompartirIgual 4.0 Internacional126546824741419-2210.1128/aac.47.4.1419-1422.2003Antimicrobial agents and chemotherapyopen access